ECSP067041A - Formulación de irinotecan - Google Patents
Formulación de irinotecanInfo
- Publication number
- ECSP067041A ECSP067041A EC2006007041A ECSP067041A ECSP067041A EC SP067041 A ECSP067041 A EC SP067041A EC 2006007041 A EC2006007041 A EC 2006007041A EC SP067041 A ECSP067041 A EC SP067041A EC SP067041 A ECSP067041 A EC SP067041A
- Authority
- EC
- Ecuador
- Prior art keywords
- irinotecan
- mol
- closed
- preparation
- blood
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una preparación de irinotecan que tiene irinotecan y/o una sal del mismo altamente portado por un portador vesicular cerrado, que muestra una retención notablemente prolongada en la sangre, como se comparó con aquella de las preparaciones de liposoma de irinotecan convencionales y es capaz de estar presente en la sangre durante un periodo de tiempo prolongado. Se proporciona una preparación de irinotecan que comprende vesículas cerradas formadas de una membrana de lípido en donde el irinotecan y/o una sal del mismo se sellan en una concentración de al menos 0.07 mol/mol (mol de medicina/mol de lípidos totales de la membrana). La preparación de irinotecan preferiblemente tiene un gradiente iónico entre una fase acuosa interna y una fase acuosa externa dentro de las vesículas cerradas. Las vesículas cerradas son preferiblemente liposomas, y los liposomas preferiblemente tienen sólo la superficie externa del mismo modificado con un modificador de superficie que contiene un polímero hidrofílico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004163742 | 2004-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP067041A true ECSP067041A (es) | 2006-12-29 |
Family
ID=35462721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2006007041A ECSP067041A (es) | 2004-06-01 | 2006-11-29 | Formulación de irinotecan |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US7846473B2 (es) |
| EP (1) | EP1752150B1 (es) |
| JP (1) | JP4885715B2 (es) |
| KR (1) | KR100889139B1 (es) |
| CN (1) | CN1960729B (es) |
| AP (1) | AP2255A (es) |
| AR (1) | AR049137A1 (es) |
| AU (1) | AU2005249314B2 (es) |
| BR (1) | BRPI0511753A (es) |
| CA (1) | CA2567857C (es) |
| CR (1) | CR8768A (es) |
| EA (1) | EA011612B1 (es) |
| EC (1) | ECSP067041A (es) |
| ES (1) | ES2594621T3 (es) |
| GE (1) | GEP20094620B (es) |
| IL (1) | IL179558A0 (es) |
| MX (1) | MXPA06013874A (es) |
| NO (1) | NO20066074L (es) |
| NZ (1) | NZ551748A (es) |
| TN (1) | TNSN06395A1 (es) |
| TW (1) | TWI362931B (es) |
| UA (1) | UA85099C2 (es) |
| WO (1) | WO2005117878A1 (es) |
| ZA (1) | ZA200610204B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101376895B1 (ko) | 2004-05-03 | 2014-03-25 | 헤르메스 바이오사이언스, 인코포레이티드 | 약물 전달에 유용한 리포좀 |
| US20090196918A1 (en) * | 2008-02-01 | 2009-08-06 | University Of Kentucky Research Foundation | Liposomal formulations of hydrophobic lactone drugs in the presence of metal ions |
| US8389768B2 (en) * | 2008-05-19 | 2013-03-05 | The University Of North Carolina At Chapel Hill | Methods and compositions comprising novel cationic lipids |
| WO2010058840A1 (ja) * | 2008-11-20 | 2010-05-27 | テルモ株式会社 | リポソームからの薬物放出手段および放出性評価法 |
| CN102271659B (zh) * | 2009-12-03 | 2013-09-18 | 江苏恒瑞医药股份有限公司 | 伊立替康或盐酸伊立替康脂质体及其制备方法 |
| CN103120645B (zh) * | 2009-12-03 | 2015-03-11 | 江苏恒瑞医药股份有限公司 | 伊立替康或盐酸伊立替康脂质体及其制备方法 |
| TWI619496B (zh) | 2011-11-03 | 2018-04-01 | 台灣微脂體股份有限公司 | 疏水性喜樹鹼衍生物之醫藥組合物 |
| US10980798B2 (en) | 2011-11-03 | 2021-04-20 | Taiwan Liposome Company, Ltd. | Pharmaceutical compositions of hydrophobic camptothecin derivatives |
| KR101842279B1 (ko) * | 2012-03-29 | 2018-03-26 | 우석대학교 산학협력단 | 이리노테칸의 안정성증진을 위한 주사제용 조성물 |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| EA023079B1 (ru) * | 2012-12-24 | 2016-04-29 | Общество С Ограниченной Ответственностью "Технология Лекарств" | Способ получения липосомальной формы иринотекана (варианты) |
| CN104906586A (zh) * | 2014-03-10 | 2015-09-16 | 中国科学院上海药物研究所 | 一种盐酸伊立替康复合磷脂组合物、制备方法及其应用 |
| CN105796495B (zh) * | 2014-12-29 | 2020-10-23 | 南京绿叶制药有限公司 | 一种盐酸伊立替康脂质体药物组合物及其制备方法 |
| CN105982857B (zh) * | 2015-02-09 | 2019-03-08 | 湖南科伦药物研究有限公司 | 一种盐酸伊立替康脂质体组合物及其制备方法 |
| ES2589320B2 (es) * | 2015-04-14 | 2017-06-01 | Universidad Politécnica de Madrid | Sistema de compartimentación de espacios con membranas enrollables |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| KR101646181B1 (ko) * | 2015-08-18 | 2016-08-05 | 한양대학교 에리카산학협력단 | 이리노테칸 함유 이중역상 온도감응성 수용성 겔 조성물 |
| EP3337467B1 (en) | 2015-08-20 | 2020-12-09 | Ipsen Biopharm Ltd. | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| IL257149B1 (en) | 2015-08-21 | 2024-07-01 | Ipsen Biopharm Ltd | Methods for treating pancreatic cancer metastases using combined treatments including liposomal irinotecan and oxaliplatin |
| CA3001467A1 (en) | 2015-10-16 | 2017-04-20 | Ipsen Biopharm Ltd. | Stabilizing camptothecin pharmaceutical compositions |
| BR112019007844A2 (pt) * | 2016-11-02 | 2019-07-16 | Ipsen Biopharm Ltd | tratamento de câncer gástrico usando terapias de combinação compreendendo irinotecano lipossômico, oxaliplatina, 5-fluoroacila (e leucovorina) |
| KR102066402B1 (ko) * | 2017-12-22 | 2020-01-15 | 대화제약 주식회사 | 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물 |
| CN109260155B (zh) | 2018-11-05 | 2021-04-06 | 杭州高田生物医药有限公司 | 伊立替康脂质体制剂及其制备与应用 |
| KR102185475B1 (ko) * | 2019-06-20 | 2020-12-02 | 대화제약 주식회사 | 이리노테칸 자유 염기를 포함하는 경구투여용 약학 조성물 |
| CA3231432A1 (en) * | 2021-10-15 | 2023-04-20 | Tianyi Ke | Composition containing antitumor drug, and preparation method therefor and use thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| IL91664A (en) * | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
| EP0721328A4 (en) | 1993-09-27 | 1997-09-17 | Smithkline Beecham Corp | CAMPTOTHECIN FORMULATIONS |
| US5827533A (en) | 1997-02-06 | 1998-10-27 | Duke University | Liposomes containing active agents aggregated with lipid surfactants |
| US6090407A (en) | 1997-09-23 | 2000-07-18 | Research Development Foundation | Small particle liposome aerosols for delivery of anti-cancer drugs |
| ATE238039T1 (de) * | 1998-09-16 | 2003-05-15 | Alza Corp | In liposomen eingeschlossene topoisomerase inhibitoren |
| JP2001064158A (ja) * | 1999-06-25 | 2001-03-13 | Terumo Corp | リポソーム |
| EP1190706B1 (en) * | 1999-06-25 | 2009-05-06 | Terumo Kabushiki Kaisha | Liposomes |
| US6352996B1 (en) | 1999-08-03 | 2002-03-05 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
| ES2253398T3 (es) * | 2000-06-30 | 2006-06-01 | Inex Pharmaceuticals Corp. | Camptotecinas liposomales mejoradas y sus usos. |
| EP1432402B1 (en) | 2001-10-03 | 2006-11-22 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| DE60237162D1 (de) | 2001-10-03 | 2010-09-09 | Celator Pharmaceuticals Inc | Liposomenladung mit metallionen |
| ES2290333T3 (es) * | 2001-11-13 | 2008-02-16 | Celator Pharmaceuticals, Inc. | Composiciones de vehiculos lipidicos y metodos para la retencion mejorada de farmacos. |
| JP4555569B2 (ja) * | 2001-11-13 | 2010-10-06 | セレーター ファーマシューティカルズ， インコーポレイテッド | 増強された血中安定性を有する脂質キャリア組成物 |
| EP1608338A1 (en) | 2003-04-02 | 2005-12-28 | Celator Technologies Inc. | Pharmaceutical compositions containing active agents having a lactone group and transition metal ions |
| KR101376895B1 (ko) * | 2004-05-03 | 2014-03-25 | 헤르메스 바이오사이언스, 인코포레이티드 | 약물 전달에 유용한 리포좀 |
| US8658203B2 (en) * | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
-
2005
- 2005-05-31 JP JP2006514098A patent/JP4885715B2/ja not_active Expired - Fee Related
- 2005-05-31 KR KR1020067025238A patent/KR100889139B1/ko active IP Right Grant
- 2005-05-31 EP EP05745848.1A patent/EP1752150B1/en active Active
- 2005-05-31 MX MXPA06013874A patent/MXPA06013874A/es not_active Application Discontinuation
- 2005-05-31 US US11/597,435 patent/US7846473B2/en active Active
- 2005-05-31 AU AU2005249314A patent/AU2005249314B2/en not_active Ceased
- 2005-05-31 ES ES05745848.1T patent/ES2594621T3/es active Active
- 2005-05-31 CN CN2005800176008A patent/CN1960729B/zh not_active Expired - Fee Related
- 2005-05-31 AP AP2006003837A patent/AP2255A/xx active
- 2005-05-31 NZ NZ551748A patent/NZ551748A/en unknown
- 2005-05-31 EA EA200602246A patent/EA011612B1/ru not_active IP Right Cessation
- 2005-05-31 UA UAA200614105A patent/UA85099C2/ru unknown
- 2005-05-31 BR BRPI0511753-4A patent/BRPI0511753A/pt not_active IP Right Cessation
- 2005-05-31 CA CA002567857A patent/CA2567857C/en not_active Expired - Fee Related
- 2005-05-31 GE GEAP20059794A patent/GEP20094620B/en unknown
- 2005-05-31 WO PCT/JP2005/009953 patent/WO2005117878A1/ja active Application Filing
- 2005-06-01 TW TW094118012A patent/TWI362931B/zh not_active IP Right Cessation
- 2005-06-01 AR ARP050102246A patent/AR049137A1/es unknown
-
2006
- 2006-11-23 CR CR8768A patent/CR8768A/es unknown
- 2006-11-23 IL IL179558A patent/IL179558A0/en unknown
- 2006-11-29 EC EC2006007041A patent/ECSP067041A/es unknown
- 2006-11-30 TN TNP2006000395A patent/TNSN06395A1/en unknown
- 2006-12-06 ZA ZA200610204A patent/ZA200610204B/xx unknown
- 2006-12-29 NO NO20066074A patent/NO20066074L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP067041A (es) | Formulación de irinotecan | |
| Rai et al. | Transfersomes as versatile and flexible nano-vesicular carriers in skin cancer therapy: The state of the art | |
| ES2922278T3 (es) | Composición de liposomas para su uso en diálisis peritoneal | |
| AU2005206163B2 (en) | Lipid-based dispersions useful for drug delivery | |
| US8062663B2 (en) | Methods and compostions for enhancing transdermal drug delivery | |
| ES2482598T3 (es) | Solución para la diálisis peritoneal | |
| KR920700679A (ko) | 비(nasal) 전달용 지질부형제와 그 사용법 | |
| JPS6230708A (ja) | リポソ−ム製剤の製造法 | |
| CU23980B1 (es) | Formulación liposomal y proceso para la preparación del mismo | |
| KR20080058438A (ko) | 생물학적 계면들로 다중 활성 약제들을 전달하기 위한이온삼투 장치 | |
| ATE71834T1 (de) | Liposomzubereitung und ihre herstellung. | |
| ES2303114T3 (es) | Metodo para cargar medicamentos en liposomas. | |
| CN105050409A (zh) | 使用大豆磷脂酰丝氨酸制备的脂质卷 | |
| UA126910C2 (uk) | Ліпосомальний препарат для застосування в лікуванні злоякісного новоутворення | |
| ES2290333T3 (es) | Composiciones de vehiculos lipidicos y metodos para la retencion mejorada de farmacos. | |
| ES2864667T3 (es) | Péptidos diseñados para la modulación de la barrera de unión estrecha | |
| BR112015023481B1 (pt) | Projeto de perfil de liberação de fármaco de controle via composição de lipossomo em ambos os compartimentos aquosos e não-aquososreferência cruzada para requerimentos relacionados | |
| WO2014026117A2 (en) | Neuroprotective liposome compositions and methods for treatment of stroke | |
| Blau et al. | Transmembrane calcium movements mediated by ionomycin and phosphatidate in liposomes with Fura 2 entrapped | |
| ES2214269T3 (es) | Composiciones liposomicas para una retencion del farmaco mejorada. | |
| JP2008195656A (ja) | 人工酸素運搬体製剤 | |
| ES2477233T3 (es) | Liposomas que contienen prostaglandina E1 (PGE1), formulaciones que los contienen y su uso | |
| PE20060484A1 (es) | Preparaciones farmaceuticas liquidas que comprenden un compuesto de benzhidril piperizina | |
| PE20130064A1 (es) | Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos | |
| US20180153805A1 (en) | A Ready-to-use Formulation for Vincristine Sulfate Liposome Injection |